When Will GLP-1 Prices Drop? The 2026–2030 Timeline
Prices verified May 22, 2026 · Updated for 2026
GLP-1 prices are already dropping and will continue declining through 2030. Key milestones: Wegovy list price cuts to $675/mo (Jan 2027), Medicare Bridge at $50/mo (July 2026), generic liraglutide already available ($200–$400/mo), and generic semaglutide expected 2031–2033. The compounded market ($99–$299/mo) remains the most affordable option until generics arrive, but the gap is narrowing every quarter.
The price is already falling — here's the map
If you've been waiting for GLP-1 prices to drop before starting treatment, the wait is effectively over. Prices have fallen 40–70% from their 2023 peaks through a combination of manufacturer programs, compounding competition, new oral entrants, and government action. But there's more coming.
The timeline
Already happened (2024–2026)
| Date | Event | Impact |
|---|---|---|
| Aug 2025 | Teva launches generic liraglutide (Saxenda equivalent) | Generic GLP-1 available for first time, $200–$400/mo |
| Nov 2025 | Novo Nordisk temporary Wegovy price cut ($199/mo for first 2 months) | Short-term promotional pricing |
| Dec 2025 | Wegovy pill FDA approved, launches at $149/mo | Oral option at compounded-competitive pricing |
| Feb 2026 | Eli Lilly launches Zepbound KwikPen at $299/mo starter | Simpler injection device, lower entry price |
| Feb 2026 | Novo Nordisk announces Wegovy list price cut to $675 (Jan 2027) | 50% list price reduction signals new pricing era |
| Apr 2026 | Foundayo (orforglipron) launches at $149/mo | Cheapest brand-name oral GLP-1 available |
Coming soon (2026–2027)
| Date | Expected event | Projected impact |
|---|---|---|
| Jul 2026 | Medicare GLP-1 Bridge launches | $50/mo for eligible Medicare Part D beneficiaries |
| Jan 2027 | Wegovy list price drops to ~$675/mo | Lowers baseline for all semaglutide pricing |
| 2026–2027 | CagriSema potential approval | New competitor adds pricing pressure |
| 2027 | Commercial insurer expansion continues | More plans cover GLP-1s for weight loss |
Medium-term (2028–2030)
| Date | Expected event | Projected impact |
|---|---|---|
| 2028–2029 | Retatrutide potential approval | Triple agonist creates new competitive tier |
| 2028–2030 | Additional oral GLP-1s enter market | Competition drives oral pricing below $100/mo |
| 2029–2030 | Medicare Prescription Drug Negotiation (Inflation Reduction Act) | GLP-1s may be selected for Medicare price negotiation |
Long-term (2031+)
| Date | Expected event | Projected impact |
|---|---|---|
| 2031–2033 | Semaglutide patent expiration / generic entry | Generic semaglutide potentially under $100/mo |
| 2033–2035 | Tirzepatide patent expiration / generic entry | Generic tirzepatide at fraction of current cost |
What this means for you right now
If you're waiting for prices to drop before starting treatment: they already have. Compounded semaglutide at $99/mo (GobyMeds), Foundayo at $149/mo, and the Wegovy pill at $149/mo are all available today. Waiting for generics (2031+) means 5+ years of untreated obesity—a medical and quality-of-life cost that dwarfs the financial cost of treatment now.
The most economically rational approach: start with the cheapest effective option today (compounded or Foundayo), and plan to transition to lower-cost options as they become available. Every year, the same treatment gets cheaper.
Will compounded GLP-1s survive?
The compounded market faces two pressures: FDA enforcement and brand-name price compression. As brand-name options approach compounded pricing ($149/mo for oral Foundayo vs $99/mo for compounded semaglutide), the regulatory risk of compounding becomes harder to justify. Our projection: compounded GLP-1s remain the cheapest option through at least 2027–2028, but the pricing advantage narrows each year. By the time generics arrive (2031+), compounded versions will likely be obsolete.
🏥 Start at Today's Prices
Compounded medications are not FDA-approved. Consult a licensed provider to determine if treatment is appropriate for you.
GobyMeds
LegitScript-verified. Semaglutide & tirzepatide bundles, free consult, free shipping.
Get StartedEmbody
Compounded semaglutide with metabolic report, 1:1 guidance, and personalized plan.
Start for $149Sesame Care
Access to FDA-approved brand-name GLP-1 medications through licensed providers.
Get StartedOak Weight Loss
Compounded semaglutide and tirzepatide at a single flat rate regardless of dose.
See PlansSources & References
- Novo Nordisk: Wegovy price reduction announcement, Feb 2026.
- Eli Lilly: Foundayo launch pricing, April 2026.
- CMS: Medicare GLP-1 Bridge program, March 2026.
- FDA: Patent expiration database (Orange Book). Accessed May 2026.
- Teva: Generic liraglutide launch, August 2025.
- Inflation Reduction Act: Medicare Drug Price Negotiation Program provisions.